A systematic approach to subgroup analyses in a smoking cessation trial

American Journal of Drug and Alcohol Abuse

Volumn 41, Issue 6, 2015, Pages 498-507

  Westover, Arthur N ^a,b   Kashner, T Michael ^a,c,d   Winhusen, Theresa M ^e   Golden, Richard M ^b   Nakonezny, Paul A ^a,b   Adinoff, Bryon ^a,f   Henley, Steven S ^c,g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g Martingale Research Corporation   (United States)

Author keywords

Attention deficit hyperactivity disorder; methylphenidate; modeling; statistics; subgroup analysis; tobacco

Indexed keywords

METHYLPHENIDATE; NICOTINE PATCH; PLACEBO; NICOTINE GUM;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BEST APPROXIMATING MODEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EFFECT SIZE; FEMALE; HUMAN; HYPOTHESIS DRIVEN APPROACH; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STATISTICAL ANALYSIS; SUBSTANCE USE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; ADOLESCENT; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944277089     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2015.1044605     Document Type: Article

References (44)

1. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statist Med 2002; 21: 2917-2930
2. Hamburg MA, Collins FS. The path to personalized medicine. New Eng J Med 2010; 363: 301-304
3. Petticrew M, Tugwell P, Kristjansson E, Oliver S, Ueffing E, Welch V. Damned if you do, damned if you dont: subgroup analysis and equity. J Epidemiol Community Health 2012; 66: 95-98
4. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet 2005; 365: 176-186
5. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 2012; 344: e1553
6. Wallace ML, Frank E, Kraemer HC. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 2013; 70: 1241-1247
7. Akaike H. Information theory and an extension the maximum likelihood principle. In: Petrov BN, Csaki F., eds. Second international symposium on information theory. Budapest: Academiai Kiado; 1973: 267-281
8. Burnham KP, Anderson DR. Model selection and multi-model inference. New York: Springer-Verlag; 2002
9. Bozdogan H. Akaikes information criterion and recent developments in information complexity. J Math Psychol 2000; 44: 62-91
10. Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2007; 68: 1094-1101
11. Golubchik P, Sever J, Weizman A. Influence of methylphenidate treatment on smoking behavior in adolescent girls with attention-deficit/hyperactivity and borderline personality disorders. Clin Neuropharmacol 2009; 32: 239-242
12. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 1680-1688
13. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7: 373-378
14. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31: 533-544
15. Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996; 123: 55-63
16. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-25
17. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127
18. Dupaul GJ, Power TJ, Anastopoulos AD. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998
19. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio, TX: The Psychological Corporation, Harcourt Brace & Company; 1996
20. Beck AT, Steer RA. Beck Anxiety Inventory: manual. San Antonio, TX: The Psychological Corporation, Harcourt Brace & Company; 1990
21. Golden R, Henley S, White H, Kashner T. New directions in information matrix testing: Eigenspectrum tests. In: Chen X, Swanson NR, eds. Recent advances and future directions in causality, prediction, and specification analysis. New York: Springer; 2013: 145-177
22. Hilbe JM. Logistic regression models. New York: Chapman and Hall; 2009
23. Nunes EV, Covey LS, Brigham G, Hu MC, Levin FR, Somoza EC, Winhusen TM. Treating nicotine dependence by targeting attention-deficit/hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response. J Clin Psychiatry 2013; 74: 983-990
24. White HL. Maximum likelihood estimation of misspecified models. Econometrica 1982; 50: 1-25
25. Claeskens G, Hjort N. Model selection and model averaging. New York: Cambridge University Press; 2009
26. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. New York: Springer-Verlag; 2001
27. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. New York: John Wiley & Sons; 2000
28. Guideline on the investigation of subgroups in confirmatory clinical trials. European Medicines Agency; 2104. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500160523.pdf
29. Golden R. Discrepancy Risk Model Selection Test theory for comparing possibly misspecified or nonnested models. Psychometrika 2003; 68: 229-249
30. Garside MJ. The best subset in multiple regression analysis. Appl Statist 1965; 14: 195-200
31. Furnival GM. All possible regressions with less computation. Technometrics 1971; 13: 403-408
32. Furnival G, Wilson R. Regression by leaps and bounds. Technometrics 1974; 16: 499-511
33. Hosmer DW, Jovanovic B, Lemeshow S. Best subsets logistic regression. Biometrics 1989; 45: 1265-1270
34. Miller A. Subset selection in regression. London: Chapman and Hall; 2002
35. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Internal Med 2009; 151: 206-209
36. Conway PH, Clancy C. Comparative-effectiveness research-implications of the Federal Coordinating Councils report. New Eng J Med 2009; 361: 328-330
37. Covey LS, Hu MC, Winhusen T, Weissman J, Berlin I, Nunes EV. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug Alcohol Depend 2010; 110: 156-159
38. Covey LS, Hu MC, Weissman J, Croghan I, Adler L, Winhusen T. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res 2011; 13: 1003-1008
39. Covey LS, Hu MC, Green CA, Brigham G, Hurt RD, Adler L, Winhusen T. An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. Am J Drug Alcohol Abuse 2011; 37: 392-399
40. Berlin I, Hu MC, Covey LS, Winhusen T. Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD. Drug Alcohol Depend 2012; 124: 268-273
41. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consulting Clin Psychol 2004; 72: 1144-1156
42. Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schauble B, et al. Predictors of treatment outcome in adults with ADHD treated with OROS(R) methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 554-560
43. Hernandez AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J 2006; 151: 257-264
44. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol 2001; 54: 979-985